WO1982003011A1 - Agent for treating deseases of respiratory organs - Google Patents
Agent for treating deseases of respiratory organs Download PDFInfo
- Publication number
- WO1982003011A1 WO1982003011A1 PCT/JP1982/000055 JP8200055W WO8203011A1 WO 1982003011 A1 WO1982003011 A1 WO 1982003011A1 JP 8200055 W JP8200055 W JP 8200055W WO 8203011 A1 WO8203011 A1 WO 8203011A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- urinary
- inhibitor
- therapeutic agent
- active ingredient
- uti
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/81—Protease inhibitors
- C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
- C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
- C07K14/8114—Kunitz type inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Definitions
- Honoki is a therapeutic agent for respiratory diseases, and more particularly, a respiratory disease containing urinary tribcine inhibitor or Z or a degradation product of urinary tribsin inhibitor as an active ingredient.
- a respiratory disease containing urinary tribcine inhibitor or Z or a degradation product of urinary tribsin inhibitor as an active ingredient.
- Emphysema has serum! (1) Eriksson et al. (J. Eriksson et al.) Journal of Brit. Staging (J, CI in «Lab. Invest.) 15th, 13th (about 3 years)]]] ?, and on the pathogenesis of pulmonary emphysema, Elixon ( (Eriksson) must not be an inhibitor of local or in-stream protein molecules from leukocytes, lungs, macrophages or microbes! (1) A theory of self-sensitivity of pulmonary tissue due to a small amount of antitribcin (a ⁇ AT) O [Actame discan and Nannabi power in av ica
- urinary tribcine inhibitors (hereinafter abbreviated as UTIs) inhibit not only tribcin but also various groups.
- UTIs urinary tribcine inhibitors
- UTI is a glycoprotein with a molecular weight of 17 000 10 to 70 000], and is derived from animals outside of humans.
- ⁇ ⁇ ⁇ ⁇ TI TI TI could be used for On the other hand, the present Kiyoshi et al.
- the active ingredient of the medical composition of the present invention is a substance that is widely present in the urine of milk horns, and its properties are slightly different depending on the type of the coming J. This is known
- the urinary tribsin inhibitor purified in this way is a ⁇ -glycoprotein having a molecular weight of ⁇ 67,000, an isoelectric point of 2-3, U, and a sugar chain of 5-1-22. .
- the ⁇ fraction is obtained by fractionating UTI with a protein component and then purifying the biochemical purification of ion-exchanged chromatography, gels, etc. You can get around the method.
- any mammal derived from mammals can be used, but even from humans, it is the best.
- the protein content of the protein is usually determined by the conventional method used to separate proteins. That is, the proteolytic enzyme was added to the appropriate buffer solution. Containing, for example, after Papai emissions solution was reacted 1 0 to alpha minute 3 7 'C before and after the addition of, gel ⁇ over and purified by the Lee on-exchange click
- the molecular weight ⁇ 5 aoc! ⁇ 9 ⁇ ⁇ Obtain fraction of ⁇ .
- the reaction mixture is once reduced by freeze-drying or the like and then subjected to a purification step, since the purification effect is enhanced.]? Further, by treating the obtained UTI component ⁇ J again with another protein-separating enzyme, for example, Vesin, etc., a component having a stronger effect can be obtained.
- proteolytic enzymes used to separate ⁇ ⁇ I include various proteolytic enzymes such as papain, pepsin, tribcine, (X-chytribushi, etc.). Although it can be used, it is particularly preferable to use papain or pepsin, and these enzymes are used in the form of a solution. It can also be used as a prime.
- the U T I component ⁇ of the Honkiaki obtained in this way is the molecular weight
- a Gore Lumpur Devon ham is te - 1 1 0 animals', TI 1 2 ⁇ g / kg-, ⁇ TI degradation product 1 ⁇ 2 / fcg- Oh Rui
- AT 30 Q was administered intravenously. Then, aspirate the 3 s Supine Pine Solution 7a with S for 3 hours.
- a tube was placed in the trachea of a white native resident rabbit weighing 2.6 ⁇ 2 ⁇ , with a group of 7 1, and placed through the tube.
- N-salt was intratracheally administered at a rate of 1 ⁇ S ⁇ day for 3 days to create swallowing pneumonia. Swallowing pneumonia created in this way
- 1 N salt was inhaled twice a day using a nebulizer for 10 minutes over a period of 3 days using a nebulizer to induce lower pneumonia.
- UTI substance 1.2 was administered to the swallowed pneumonia specimen prepared in this manner for 4 days during the salt administration period.
- the carotid artery was cut off and exsanguinated, and a large amount of physiological saline was perfused from the pulmonary artery under a constant pressure.
- the lungs were removed, and the lungs were homogenized by adding physiological saline to the lungs for 1 ml / liter, and the resulting homogenate was added to quantify the amount of phospholipids.
- Control group 3 8 0 0 ⁇ 4 3 0
- a ddy mouse with a body weight of about 20 ⁇ is 1a per group, and 2 of the UTI, UTI decomposed product, or a mixture containing UTI and UTI product in a ratio of 10: 1 are physiologically administered.
- the solution was injected intravenously or intraperitoneally as a saline solution, and the symptoms were observed for one week. Changes in body weight during the observation period were similar to those in the saline-administered group, and there were deaths. There were no abnormalities in the autopsy findings after convulsions for one week and one week. won.
- UTIs and / or UTI derivatives can be extremely useful for the prevention and treatment of various respiratory diseases, including adipose, pneumonia, and rubella fibrosis. It is. * Good form for practicing the invention
- the therapeutic dose of the ⁇ ⁇ I and / or ⁇ I sculptures of Honkiaki is 1 day]? 1 ⁇ 100?, Preferably 50 ⁇ 500, It can be reduced as appropriate depending on the symptoms and usage.
- composition I and / or UTI of the present invention is usually administered as an injection or an inhalant, but is given as an oral preparation or a drug for Xinjiang. You can also. Lyophilized preparation used as an injection and inhalant after dissolving at the time of use; oral preparations such as capsules, tablets, granules, powders, or liquid preparations for oral use Although it is possible to do so, it is preferable to use ribosome inclusions to promote absorption. It is appropriate to use direct suppositories as direct abuse agents. In preparing these preparations, a method of resentment can be used together with a conventional manufacturing carrier or excipient.
- the method for obtaining UTI will be described with reference to examples.
- the method for obtaining UTI is not limited to these examples, and it goes without saying that a method for purifying a killing protein is used. That is.
- Formulations of the present pharmaceutical composition are shown below as Examples.
- the agent is not limited to this.
- the bovine blood albumin is used as the target protein, and the protein content is measured, and adjusted by adding physiological saline to obtain 10 / ⁇ . After sterilizing the bacteria with a filter, dispensing 1 ⁇ 77 ⁇ at a time into a glass container, freeze-drying and sealing, then use as a freeze-dried filler.
- the fractions having a molecular weight of 0 Qaa to 7 aao were collected.
- the protein content of this fraction was measured in the same manner as in Example 2, adjusted to 1 a with physiological saline, and then sterilized with a membrane filter to remove bacteria. Dispense the liquid into glass containers at 5 ffl each time to obtain injection solution.
- Example 5 Solution for Injection ⁇ UTI Degraded Product 1 ⁇ of Molecular Weight ⁇ to 7 ⁇ Obtained by the Method of Example 4 and Human ⁇ ⁇ ⁇ 1 were replaced with 1 1 (30% of physiological saline) The solution is sterilized by a membrane filter, and the solution is dispensed into glass containers by 5 ⁇ each to obtain a liquid preparation for injection.
- Egg yolk lecithin, cholesterol, and diethylene glycol phosphate are mixed at a molar ratio of 7: 2: 1, and the ⁇ is mixed.
- the film was infiltrated into a 15-meter black mouth film, and a thin film was prepared on a glass wall.
- Honjoki is useful as a therapeutic agent for pulmonary emphysema, pneumonia, pulmonary fibrosis and other respiratory laughter.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pulmonology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Dispersion Chemistry (AREA)
- Epidemiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Description
Claims
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE823235923T DE3235923T1 (de) | 1981-03-02 | 1982-03-01 | Therapeutisches mittel zur behandlung von erkrankungen der atemwege |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP56029650A JPS57144224A (en) | 1981-03-02 | 1981-03-02 | Remedy for respiratory dieseases |
JP81/29650810302 | 1981-03-02 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1982003011A1 true WO1982003011A1 (en) | 1982-09-16 |
Family
ID=12281975
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP1982/000055 WO1982003011A1 (en) | 1981-03-02 | 1982-03-01 | Agent for treating deseases of respiratory organs |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP0073251B1 (ja) |
JP (1) | JPS57144224A (ja) |
CA (1) | CA1181006A (ja) |
DE (1) | DE3235923T1 (ja) |
GB (1) | GB2122486B (ja) |
WO (1) | WO1982003011A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5650394A (en) * | 1993-11-04 | 1997-07-22 | Adeza Biomedical | Use of urinastatin-like compounds to prevent premature delivery |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0100964A3 (de) * | 1982-07-31 | 1984-06-13 | Reifenrath, Rainer, Dr. | Pharmazeutisches Erzeugnis zur Behandlung und Prophylaxe von Infektionen sowie von Husten und obstruktiven Atemwegserkrankungen sowie Verfahren zu seiner Herstellung |
JPS6137736A (ja) * | 1984-07-31 | 1986-02-22 | Nippon Chem Res Kk | 人尿トリプシンインヒビタ−製剤の製法 |
FI854634A0 (fi) * | 1985-11-22 | 1985-11-22 | Labsystems Oy | Foerfarande foer bestaemning av proteolytisk aktivitet. |
EP0255011A3 (en) * | 1986-07-29 | 1988-11-23 | Miles Inc. | Human inter-alpha-trypsin inhibitor gene |
JP2656944B2 (ja) * | 1987-04-30 | 1997-09-24 | クーパー ラボラトリーズ | タンパク質性治療剤のエアロゾール化 |
JP2804979B2 (ja) * | 1988-11-28 | 1998-09-30 | 日本ケミカルリサーチ株式会社 | エイズ治療および阻害剤 |
US5409895A (en) * | 1990-11-13 | 1995-04-25 | Mochida Pharmaceutical Co., Ltd. | Protease inhibitory polypeptides derived from urinary trypsin inhibitor and compositions thereof |
CA2082226A1 (en) * | 1991-11-08 | 1993-05-09 | Hideaki Morishita | Polypeptide, dna fragment encoding the same, drug composition containing the same and process for producing the same |
WO2003090682A2 (en) * | 2002-04-25 | 2003-11-06 | The Scripps Research Institute | Treatment and prevention of pulmonary conditions |
GB0507577D0 (en) * | 2005-04-14 | 2005-05-18 | Novartis Ag | Organic compounds |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS57140728A (en) * | 1981-02-26 | 1982-08-31 | Mochida Pharmaceut Co Ltd | Decomposition product of substance inhibiting trypsin in urine |
-
1981
- 1981-03-02 JP JP56029650A patent/JPS57144224A/ja active Granted
-
1982
- 1982-03-01 CA CA000397353A patent/CA1181006A/en not_active Expired
- 1982-03-01 WO PCT/JP1982/000055 patent/WO1982003011A1/ja active IP Right Grant
- 1982-03-01 GB GB08229371A patent/GB2122486B/en not_active Expired
- 1982-03-01 DE DE823235923T patent/DE3235923T1/de active Granted
- 1982-03-01 EP EP82900660A patent/EP0073251B1/en not_active Expired
Non-Patent Citations (1)
Title |
---|
No relevant documents have been disclosed * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5650394A (en) * | 1993-11-04 | 1997-07-22 | Adeza Biomedical | Use of urinastatin-like compounds to prevent premature delivery |
Also Published As
Publication number | Publication date |
---|---|
CA1181006A (en) | 1985-01-15 |
JPS57144224A (en) | 1982-09-06 |
GB2122486A (en) | 1984-01-18 |
EP0073251A4 (en) | 1983-07-08 |
JPS6237615B2 (ja) | 1987-08-13 |
EP0073251B1 (en) | 1986-06-11 |
GB2122486B (en) | 1985-02-27 |
EP0073251A1 (en) | 1983-03-09 |
DE3235923C2 (ja) | 1988-05-26 |
DE3235923T1 (de) | 1983-02-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TWI457132B (zh) | 含表面活性蛋白b(sp-b)及表面活性蛋白c(sp-c)類似物之改良重組表面活性劑組成物 | |
AU691514B2 (en) | Stabilization of aerosolized proteins | |
JP2008031184A (ja) | 気道流路および肺疾患の処置のためのモメタゾンフロエートの使用 | |
ES2887358T3 (es) | Inhibidor de Alfa1-Proteinasa para demorar el comienzo o progresión de exacerbaciones pulmonares | |
JP2774379B2 (ja) | 医薬エアロゾール組成物ならびにそれらのウイルス疾患の治療および予防用途 | |
US4916117A (en) | Treatment of inflammation using alpha 1-antichymotrypsin | |
WO1982003011A1 (en) | Agent for treating deseases of respiratory organs | |
CA3024522A1 (en) | Beta-hairpin peptidomimetic with elastase inhibitory activity and aerosol dosage forms thereof | |
US6124257A (en) | Method of treatment | |
CN104955469B (zh) | Sp肽或其衍生物在制备预防或治疗哮喘的药物中的应用 | |
CA2365266A1 (en) | Soybean protein nutraceuticals | |
US20140023629A1 (en) | Ameliorating agent for chronic obstructive pulmonary disease | |
JP7546566B2 (ja) | 疣贅の治療 | |
CN100594930C (zh) | 以垂体前叶肾上腺皮质提取物为主要成份的组合药物及其制备方法和用途 | |
CN104918629B (zh) | Sp肽或其衍生物在制备降低il‑13水平的药物中的应用 | |
US20230113110A1 (en) | Composition for the treatment of lesions of the respiratory system | |
WO1995025539A1 (fr) | Nouveau remede contre les maladies virales des voies respiratoires | |
JPS6029688B2 (ja) | 医療用カリクレイン製剤 | |
WO1992011022A1 (en) | Pharmaceutical preparation for pernasal administration | |
CN115006532A (zh) | 蛋白酶体抑制剂的应用 | |
CA3177764A1 (en) | Beta thymosin peptides for treating viral infections | |
KR101580313B1 (ko) | Dna 메틸트랜스퍼레이즈 저해제를 유효성분으로 포함하는 hbv의 감염에 의한 간 손상 복구용 조성물 | |
JPH05163158A (ja) | 人尿性キニノゲナーゼを有効成分とする皮膚潰瘍の予防及び治療剤 | |
JPS58225026A (ja) | アミラ−ゼ活性および/またはリパ−ゼ活性亢進に起因する疾患の予防および治療剤 | |
AU605580B2 (en) | Aerosolization of protein therapeutic agent |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Designated state(s): DE GB US |
|
AL | Designated countries for regional patents |
Designated state(s): FR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1982900660 Country of ref document: EP |
|
RET | De translation (de og part 6b) |
Ref document number: 3235923 Country of ref document: DE Date of ref document: 19830224 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 3235923 Country of ref document: DE |
|
WWP | Wipo information: published in national office |
Ref document number: 1982900660 Country of ref document: EP |
|
WWG | Wipo information: grant in national office |
Ref document number: 1982900660 Country of ref document: EP |